GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (OTCPK:MVRBF) » Definitions » Cyclically Adjusted PS Ratio

Medivir AB (Medivir AB) Cyclically Adjusted PS Ratio : (As of Apr. 30, 2024)


View and export this data going back to . Start your Free Trial

What is Medivir AB Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Medivir AB Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Medivir AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medivir AB Cyclically Adjusted PS Ratio Chart

Medivir AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.88 0.60 1.15 1.02 0.40

Medivir AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.02 0.87 0.77 0.78 0.40

Competitive Comparison of Medivir AB's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Medivir AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medivir AB's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medivir AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Medivir AB's Cyclically Adjusted PS Ratio falls into.



Medivir AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Medivir AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Medivir AB's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.008/130.9575*130.9575
=0.008

Current CPI (Dec. 2023) = 130.9575.

Medivir AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.847 99.788 1.112
201406 2.216 100.432 2.890
201409 2.252 100.161 2.944
201412 1.289 100.225 1.684
201503 0.706 99.950 0.925
201506 0.834 99.995 1.092
201509 0.377 100.228 0.493
201512 -0.324 100.276 -0.423
201603 0.075 100.751 0.097
201606 0.134 101.019 0.174
201609 0.091 101.138 0.118
201612 0.033 102.022 0.042
201703 0.069 102.022 0.089
201706 0.038 102.752 0.048
201709 0.026 103.279 0.033
201712 0.020 103.793 0.025
201803 0.019 103.962 0.024
201806 0.011 104.875 0.014
201809 0.011 105.679 0.014
201812 0.051 105.912 0.063
201903 0.007 105.886 0.009
201906 0.013 106.742 0.016
201909 0.006 107.214 0.007
201912 0.005 107.766 0.006
202003 0.031 106.563 0.038
202006 0.018 107.498 0.022
202009 0.005 107.635 0.006
202012 0.006 108.296 0.007
202103 0.026 108.360 0.031
202106 0.002 108.928 0.002
202109 0.002 110.338 0.002
202112 0.028 112.486 0.033
202203 0.001 114.825 0.001
202206 0.001 118.384 0.001
202209 0.002 122.296 0.002
202212 0.004 126.365 0.004
202303 0.001 127.042 0.001
202306 0.003 129.407 0.003
202309 0.001 130.224 0.001
202312 0.008 130.958 0.008

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Medivir AB  (OTCPK:MVRBF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Medivir AB Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Medivir AB's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Medivir AB (Medivir AB) Business Description

Industry
Traded in Other Exchanges
Address
Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.